Cardiac T1 Mapping and ECV Phantom (T1MES) What is T1MES? The T1 Mapping and ECV Standardization Program (“T1MES”) was developed to explore T1 mapping quality assurance on 1.5 and 3T magnets across numerous CMR centres worldwide. This program progressed with the development and regulatory approval of a T1MES phantom. The T1MES Phantom was originally designed by […]
Bone Marrow R2-MRI is an MRI-based solution for assessing iron levels in the bone marrow. Both decreased and increased bone marrow iron are of clinical significance; for example multiple blood transfusions can result in greatly increased bone marrow iron and conversely, the definitive test of iron deficiency is examination of iron from bone marrow aspirates.
Bone Marrow R2-MRI Read More »
An increasing number of patient treatment guidelines for thalassaemia, sickle cell disease, myelodysplastic syndrome and haemochromatosis recommend using MRI to quantitatively measure liver iron concentration. Please note that a reference to R2 MRI is referring to FerriScan. The following are excerpts from treatment guidelines – click on the title to view the full document. UK
FerriScan: Patient Management Guidelines Read More »
Iron overload is increasingly recognised as a possible complication in cancer survivors who received multiple blood transfusions as part of their cancer therapy. Iron overload can result from treatments for both blood and solid tumours and can persist for years after cancer treatment. Excess iron is deposited in tissues of the body, potentially causing tissue
Iron Overload in Cancer Survivors Read More »
Resonance Health currently has two products on the market; FerriScan® (with or without a Cardiac T2* component) and HepaFat-Scan®. These products are magnetic resonance imaging based solutions that provide quantitative liver measurements, with the distinctive advantage over liver biopsy of being non-invasive. The products are provided via a unique Quality Assured Service Delivery model. All
HepaFat-Scan is a magnetic resonance imaging (MRI)-based technology for the non-invasive measurement of liver fat. It provides a reliable measure of volume percentage of liver fat for screening, diagnosis, treatment planning and monitoring of patients in a variety of clinical settings. What Does HepaFat-Scan Offer You? A non-invasive – safe and painless alternative to liver
HepaFat-Scan® Information for Patients Read More »
Potential Clinical Applications Gastroenterology and Hepatology Applications Initial workup for NAFLD diagnosis and for patient education and counselling. Liver fat analysis on patients already being screened or monitored for fibrosis or cirrhosis. Recent research indicates that patients with NAFLD and NASH can develop liver cancer without progressing through cirrhosis. Surgical Applications Scanning of patients with
HepaFat-Scan® Information for Clinicians Read More »
Non-alcoholic fatty liver disease (NAFLD) is a name that is given to a range of liver disorders associated with the presence of too much fat in the liver. Steatosis is a mild form of fatty liver. In some patients with steatosis, inflammation of the liver may occur with resultant hepatitis called non-alcoholic steatohepatitis (NASH). Risk
Fatty Liver Disease Read More »
HepaFat-Scan is a non-invasive MRI-based solution for measuring the volume fraction of fat in liver tissue. HepaFat-Scan is provided as an image analysis service; with analysis and reporting provided from the Resonance Health ISO 13485 certified Service Centre via our Quality Assured Service Delivery model. The HepaFat-Scan software is the first and only method with
HepaFat-Scan® – MRI Measurement of Liver Fat Read More »
Canada FerriScan is reimbursed in all Canadian provinces as an 'Out-of-Country Medical Service'. The treating clinician must forward an application for each patient to the province's Ministry of Health (MOH) for approval. Once approved, the MOH will grant a timeframe for the patient to have their FerriScan and/or Cardiac T2*. To help with the application
INVESTORS
SUPPORT
PATIENTS
PHYSICIANS